Vitrakvi is a prescription medicine used to treat adults and children with solid tumors that have a specific genetic feature known as an NTRK gene fusion. It is used when the cancer has spread or cannot be surgically removed and there are no satisfactory alternative treatments.
Larotrectinib
Generic Name/API:Larotrectinib
Packaging:For Capsule: each bottle contains 56 capsules, For Oral solution: 20 mg/mL of larotrectinib
Storage:Capsules are stored at 20°C to 25°C while oral solution is to be stored at 2°C to 8°C.
Dosage:For dosage information, please check the General Information section.
Strength:The capsules are available in strengths of 25mg and 100mg. Oral solution consists of 20mg/ml of larotrectinib.
Indication:Vitrakvi is a targeted cancer therapy used to treat solid tumors with NTRK gene fusions. It works by inhibiting TRK fusion proteins that promote cancer growth. Approved by the FDA in 2018, it can be used regardless of tumor type when no other treatment options are effective.
Vitrakvi is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, without a known acquired resistance mutation. These tumors must be either metastatic or where surgical resection is likely to result in severe morbidity, and there must be no satisfactory alternative treatments or the cancer must have progressed following treatment. This indication is tumor-agnostic, meaning Vitrakvi is approved based on the presence of the NTRK gene fusion rather than the location or type of the cancer, making it suitable for various tumor types such as lung, thyroid, colon, and pediatric cancers like infantile fibrosarcoma.
Strength:
The capsules are available in strengths of 25mg and 100mg. Oral solution consists of 20mg/ml of larotrectinib.
Dosage:
- Adults and Pediatric Patients with Body Surface Area (BSA) ≥1 m²: 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity occurs.
- Pediatric Patients with BSA <1 m²: 100 mg/m² orally twice daily, with a maximum dose of 100 mg per dose, until disease progression or unacceptable toxicity occurs.
Dose modification for adverse reactions:
| Dosage Modification | Adult and Pediatric Patients with Body Surface Area of at Least 1.0 m2 | Pediatric Patients with Body Surface Area Less Than 1.0 m2 |
| First | 75 mg orally twice daily | 75 mg/m2 orally twice daily |
| Second | 50 mg orally twice daily | 50 mg/m2 orally twice daily |
| Third | 100 mg orally once daily | 25 mg/m2 orally twice daily |
Side effects
- Neurological effects
- Bone fracture
- Liver toxicity
Storage:
Capsules can be stored at 20°C to 25°C and oral solutions can be stored at 2°C to 8°C.
- Neurotoxic effects have been observed in patients receiving Vitrakvi. Patients should be monitored for neurological symptoms, and dose modifications may be necessary based on severity.
- Hepatic adverse reactions, including elevated liver enzymes, have been reported. Liver function tests should be conducted prior to initiating treatment and monitored regularly during therapy.
- Vitrakvi can cause fetal harm when administered to pregnant women. Female patients of reproductive potential should be advised of the potential risk to a fetus and use effective contraception during treatment and for at least 1 week after the final dose.
FAQ
Who can take Vitrakvi?
Vitrakvi is approved for:
-
Adult and pediatric patients with solid tumors that have an NTRK gene fusion,
-
Whose cancer is metastatic or where surgery is likely to cause severe morbidity,
-
And who have no satisfactory alternative treatments or whose cancer has progressed on treatment.
Genetic testing must confirm the presence of an NTRK gene fusion before starting treatment.
How is Vitrakvi taken?
Vitrakvi is available as:
-
Oral capsules for adults
-
Oral solution for children or adults who cannot swallow capsules
It is usually taken twice daily, with or without food. Dosage is based on body weight and age.
Can Vitrakvi be used in combination with other cancer therapies?
Currently, Vitrakvi is approved as a single-agent therapy.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certification and possesses a valid operating license. These credentials confirm the supplier’s adherence to international standards for the proper distribution of medicinal products.
What is the cost of Vitrakvi (larotrectinib) in India?
The cost of Vitrakvi (Larotrectinib) in India varies as it is not locally available and must be imported. Factors such as currency exchange rates, import duties, and supplier availability can affect the final price. For the latest cost details, please contact 24/7 QualityMeds at +91 9967979080.
How to buy vitrakvi (larotrectinib) online in India?
To buy vitrakvi (larotrectinib) in India at a genuine price, contact 24/7 QualityMeds. We provide complete assistance in importing this medicine legally and ensure safe delivery at the best possible cost.
